EU MDR Transition: Lessons from First Full Enforcement Year

EU MDR: One Year of Full Enforcement

The European Medical Device Regulation has now been fully in force for one year, providing sufficient data to assess implementation challenges and industry adaptation. This analysis examines key lessons and ongoing compliance challenges.

Implementation Reality Check

The transition has revealed:

• Notified Body Bottlenecks: Capacity constraints continue to delay certifications
• Legacy Device Challenges: Many devices required complete recertification
• Documentation Gaps: Clinical evaluation requirements exceeded many manufacturers' capabilities
• Supply Chain Disruptions: Some devices withdrawn from EU markets

Clinical Evidence Expectations

The elevated clinical evidence bar has required:

• Expanded clinical investigations for certain device types
• More rigorous post-market clinical follow-up
• Enhanced real-world evidence collection capabilities
• Greater investment in clinical affairs functions

Successful Transition Strategies

Organizations navigating MDR effectively have:

• Started early with comprehensive gap assessments
• Invested heavily in clinical and regulatory capabilities
• Engaged proactively with notified bodies
• Prioritized device portfolio rationalization
• Built robust quality management systems

Ongoing Challenges

Persistent issues include:

• Timeline unpredictability for certification reviews
• Varying interpretations across notified bodies
• Resource constraints for smaller manufacturers
• IVDR transition adding additional burden

Recommendations for Continued Compliance

• Maintain ongoing regulatory intelligence monitoring
• Build flexible resource models to address certification demands
• Invest in clinical evidence generation infrastructure
• Strengthen post-market surveillance capabilities
• Engage with industry associations on implementation guidance